|
|
1.
|
Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS). MedStar authors:
Year: 2017
Citation: - Diabetic Medicine. 34(12):1747-1755, 2017 Dec.
Institution: - MedStar Health Research Institute
Medline publication type:
All authors: - Aroda VR, Barrett-Connor E, Dabelea D, Dagogo-Jack S, Hamman RF, Kahn SE, Knowler WC, Mather KJ, Pan Q, Perreault L, The Diabetes Prevention Program Research Group
|
|
|
2.
|
Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors. MedStar authors:
Year: 2013
Citation: - Arteriosclerosis, Thrombosis & Vascular Biology. 33(2):393-9, 2013 Feb.
Institution: - MedStar Health Research Institute
Medline publication type:
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- Research Support, U.S. Gov't, Non-P.H.S.
All authors: - Banerji M, Bray GA, Buchanan TA, Clement SC, DeFronzo RA, Henry RR, Hodis HN, Kitabchi AE, Mack WJ, Mudaliar S, Musi N, Ratner RE, Reaven PD, Saremi A, Schwenke DC, Stentz FB, Tripathy D
|
